

GCLM Antibody (monoclonal) (M02)

Mouse monoclonal antibody raised against a full-length recombinant GCLM. Catalog # AT2178a

Specification

GCLM Antibody (monoclonal) (M02) - Product Information

Application WB **Primary Accession** P48507 Other Accession BC041809 Reactivity Human, Rat Host mouse Clonality **Monoclonal** IgG2a Lambda Isotype 30727

Calculated MW

GCLM Antibody (monoclonal) (M02) - Additional Information

Gene ID 2730

Other Names

Glutamate--cysteine ligase regulatory subunit, GCS light chain, Gamma-ECS regulatory subunit, Gamma-glutamylcysteine synthetase regulatory subunit, Glutamate--cysteine ligase modifier subunit, GCLM, GLCLR

Target/Specificity

GCLM (AAH41809, 1 a.a. ~ 274 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Dilution

WB~~1:500~1000

Clear, colorless solution in phosphate buffered saline, pH 7.2.

Storage

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions

GCLM Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.

GCLM Antibody (monoclonal) (M02) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides




- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

GCLM Antibody (monoclonal) (M02) - Images



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (55.88 KDa).



GCLM monoclonal antibody (M02), clone 2C6. Western Blot analysis of GCLM expression in PC-12 ((Cat # AT2178a)

GCLM Antibody (monoclonal) (M02) - Background

Glutamate-cysteine ligase, also known as gamma-glutamylcysteine synthetase, is the first rate limiting enzyme of glutathione synthesis. The enzyme consists of two subunits, a heavy catalytic subunit and a light regulatory subunit. Gamma glutamylcysteine synthetase deficiency has been implicated in some forms of hemolytic anemia.

GCLM Antibody (monoclonal) (M02) - References

Assessing oxidative pathway genes as risk factors for bipolar disorder. Fullerton JM, et al. Bipolar Disord, 2010 Aug. PMID 20712757. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedine-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID







20628086. Accumulation of gene polymorphisms related to oxidative stress is associated with myocardial infarction in Japanese type 2 diabetic patients. Katakami N, et al. Atherosclerosis, 2010 Jun 12. PMID 20598694. Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population. Wang Y, et al. J Hum Genet, 2010 Aug. PMID 20485444. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Moyer AM, et al. Cancer Epidemiol Biomarkers Prev, 2010 Mar. PMID 20200426.